Bedrijfsoverzicht
Alkermes plc is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of pharmaceutical products aimed at addressing unmet medical needs for patients across therapeutic areas in the United States, Ireland, and international markets. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which positions it as a provider of specialized therapeutic solutions rather than broad-spectrum generic drugs. Alkermes plc currently holds a market capitalization of $5.56B, generates an annual revenue of $1.48B, and employs a workforce of 2050 individuals to execute its business strategy. These valuation and revenue figures indicate that the company maintains a substantial market presence, allowing it to invest in proprietary commercial portfolios while navigating the complex regulatory and competitive landscape of the specialty pharmaceutical industry.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $1.48B with a corresponding net income of $241.66M and an EBITDA of $281.12M. The significant gap between the $1.48B revenue and the $241.66M net income reveals a robust cost structure where operational expenses and taxes consume approximately 83.6% of gross revenue before arriving at the bottom line. However, the free cash flow stands at -$363,090,624, which indicates that despite generating substantial accounting profits, the company is currently burning cash, likely due to heavy capital expenditures or working capital requirements associated with its R&D and commercialization activities. Profitability efficiency is evident through three key margins: a gross margin of 86.7%, an operating margin of 15.1%, and a profit margin of 16.4%. The high gross margin of 86.7% suggests strong pricing power and favorable cost of goods sold dynamics, while the operating margin of 15.1% reflects the efficiency of the company's overhead management. The profit margin of 16.4% further confirms that after all expenses, including taxes and interest, the company retains a healthy portion of revenue as profit. Regarding liquidity and leverage, the company holds $588.21M in cash against only $70.00M in debt, supported by a debt-to-equity ratio of 3.85. Although the debt-to-equity ratio of 3.85 indicates a leveraged balance sheet relative to equity, the substantial cash reserve provides a significant buffer against short-term obligations and interest payments. Short-term liquidity is further secured by a current ratio of 3.55, which demonstrates that the company possesses more than three times the current assets necessary to cover its current liabilities. Return metrics show a return on equity of 14.7% and a return on assets of 7.0%, indicating that management is generating solid returns on the shareholders' invested capital and utilizing the company's asset base effectively to generate earnings.
Waarderingsbeoordeling
The valuation multiples for Alkermes plc include a trailing P/E ratio of 23.33 and a forward P/E of 16.73. The notable difference between the trailing P/E of 23.33 and the forward P/E of 16.73 implies that the market expects earnings to expand significantly in the future, as investors are pricing in a substantial improvement in profitability relative to current levels. The price-to-book ratio stands at 3.04, indicating that the market values the company at more than three times its book value, reflecting a premium assigned to its intangible assets, proprietary drug portfolio, and future growth potential. Alternative valuation metrics such as the price-to-sales ratio of 3.77 and an EV/EBITDA of 17.93 provide additional context; the P/S ratio suggests the company is valued at nearly four times its revenue, which is typical for high-growth biopharmaceutical firms, while the EV/EBITDA of 17.93 places the company's enterprise value relative to cash flow in a moderate range for the sector. Price momentum is observed within a 52-week trading range defined by a high of $36.48 and a low of $25.17. Without the current stock price explicitly listed in the provided facts, the absolute percentage distance cannot be calculated, but the range establishes the volatility boundaries within which the stock has traded over the past year. The stock exhibits a beta of 0.39, which means its price volatility is significantly lower than the broader market, suggesting that the stock price moves with less intensity than the overall market index.
Growth & Income
Recent performance data shows a revenue growth of -10.6% year-over-year and an earnings growth of -67.0% year-over-year. The disparity between the -10.6% revenue decline and the -67.0% earnings contraction implies that earnings are falling much faster than revenue, likely driven by non-recurring costs, margin compression, or one-time charges impacting the net income calculation disproportionately. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its earnings and cash reserves into research, development, and commercialization efforts rather than distributing cash to shareholders. This strategy is common for biopharmaceutical companies prioritizing portfolio expansion and R&D pipelines over immediate shareholder returns. The overall growth and income profile currently reflects a contractionary phase where the company sacrifices immediate income distribution and revenue stability to potentially secure long-term growth through its proprietary commercial portfolio and ongoing therapeutic innovations.